BIOSPECIFICS TECHNOLOGIES CORP
NT 10-Q, 1999-06-15
PHARMACEUTICAL PREPARATIONS
Previous: FILENES BASEMENT CORP, 10-Q, 1999-06-15
Next: BIOSPECIFICS TECHNOLOGIES CORP, NT 10-Q/A, 1999-06-15



                                                 -------------------------------
      UNITED STATES                                    OMB APPROVAL
SECURITIES AND EXCHANGE COMMISSION
      Washington, D.C. 20549                     -------------------------------
                                                 -------------------------------
                                                 OMB Number:  3235-0058
      FORM 12b-25                                Expires:           May 31, 1997
                                                 Estimated average burden
                                                 hours per response. . . . .2.50
                                                 -------------------------------


   NOTIFICATION OF LATE FILING                   -------------------------------
                                                          SEC FILE NUMBER
                                                          0-19879
                                                 -------------------------------
                                                 -------------------------------
                                                          CUSIP NUMBER
                                                          090931 106
                                                 -------------------------------

(Check One): [ ]Form 10-K [ ]Form 20-F [ ]Form 11-K [X]Form 10-Q [ ]Form N-SAR

                 For Period Ended:  April 30, 1999
                                    -----------------------
                 [ ] Transition Report on Form 10-K
                 [ ] Transition  Report on Form 20-F
                 [ ] Transition Report on Form 11-K
                 [ ] Transition Report on Form 10-Q
                 [ ] Transition Report on Form N-SAR
                 For the Transition Period Ended:
                                                  ------------------------------
________________________________________________________________________________
  Read Instruction (on back page) Before Preparing Form. Please Print or Type.
    Nothing in this form shall be construed to imply that the Commission has
                   verified any information contained herein.
________________________________________________________________________________

If the notification  relates to a portion of the filing checked above,  identify
the Item(s) to which the notification relates:
________________________________________________________________________________

PART I - REGISTRANT INFORMATION
________________________________________________________________________________
Full Name of Registrant
                           BioSpecifics Technologies Corp.
________________________________________________________________________________
Former Name if Applicable
                           N/A
________________________________________________________________________________
Address of Principal Executive Office (Street and Number)
                           35 Wilbur Street
________________________________________________________________________________
City, State and Zip Code
                           Lynbrook, New York  11563

PART II - RULES 12b-25(b) AND (c)

If the subject report could not be filed without  unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed. (Check box if appropriate)

                     (a)  The reasons described in reasonable detail in Part III
                          of  this  form   could  not  be   eliminated   without
                          unreasonable effort or expense;
                     (b)  The  subject   annual  report,   semi-annual   report,
                          transition  report on Form 10-K,  Form  20-F,  11-K or
                          Form N-SAR,  or portion  thereof,  will be filed on or
                          before  the  fifteenth   calendar  day  following  the
[X]                       prescribed due date; or the subject  quarterly  report
                          of transition  report on Form 10-Q, or portion thereof
                          will be filed on or  before  the  fifth  calendar  day
                          following the prescribed due date; and
                     (c)  The  accountant's  statement or other exhibit required
                          by Rule 12b-25(c) has been attached if applicable.

PART III - NARRATIVE

State below in reasonable  detail the reasons why Forms 10-K,  20-F, 11-K, 10-Q,
N-SAR, or the transition  report or portion  thereof,  could not be filed within
the prescribed time period. (Attach extra sheets if needed.)

         The Company's  Quarterly Report on Form 10-QSB will not be filed within
the prescribed  time period  because of unexpected  delays in preparation of the
narrative  section and the  calculation of the provision for income taxes of the
Form 10-QSB.
<PAGE>

PART IV - OTHER INFORMATION

(1)      Name and  telephone  number  of  person  to  contact  in regard to this
         notification

         Albert Horcher           516                        593-7000
         _____________________    ____________________       ___________________
         (Name)                   (Area Code)                (Telephone Number)

(2)      Have all other periodic  reports  required under Section 13 or 15(d) of
         the  Securities  Exchange  Act of 1934 or Section 30 of the  Investment
         Company Act of 1940 during the  preceding 12 months or for such shorter
         period that the  registrant  was required to file such  report(s)  been
         filed? If answer is no, identify report(s).

                                                        [X]Yes   [ ]No
         _______________________________________________________________________

(3)      Is it anticipated that any significant  change in results of operations
         from  the  corresponding  period  for  the  last  fiscal  year  will be
         reflected  by the  earnings  statements  to be  included in the subject
         report or portion thereof?

                                                        [X]Yes   [ ]No

         If  so,  attach  an  explanation  of  the  anticipated   change,   both
         narratively and quantitatively,  and, if appropriate, state the reasons
         why a reasonable estimate of the results cannot be made.


                 The Company expects to report a loss of approximately  $125,000
         to $175,000 for the fiscal quarter. The exact amount of the loss is not
         calculable until the provision for income taxes is calculated.

                         BioSpecifics Technologies Corp.
                ________________________________________________
                   (Name of Registrant as Specified in Charter

has  caused  this  notification  to be signed on its  behalf by the  undersigned
hereunto duly authorized.

Date June 15, 1999                  By  /S/ ALBERT HORCHER
     ______________________________     __________________________________

INSTRUCTION: The form may be signed by an executive officer of the registrant or
by any other duly  authorized  representative.  The name and title of the person
signing  the form  shall  be typed or  printed  beneath  the  signature.  If the
statement is signed on behalf of the registrant by an authorized  representative
(other than an executive officer), evidence of the representative's authority to
sign on behalf of the registrant shall be filed with the form.

                                    ATTENTION
________________________________________________________________________________
   Intentional misstatements or omissions of fact constitute Federal Criminal
                        Violations (See 18 U.S.C. 1001).
________________________________________________________________________________
                              GENERAL INSTRUCTIONS

1.       This form is required by Rule 12b-25 (17 CFR 240.12b-25) of the General
         Rules and Regulations under the Securities Exchange Act of 1934.

2.       One  signed  original  and  four  conformed  copies  of this  form  and
         amendments  thereto must be completed and filed with the Securities and
         Exchange  Commission,  Washington,  D.C. 20549, in accordance with Rule
         0-3 of the General Rules and Regulations under the Act. The information
         contained  in or filed  with the form  will be made a matter  of public
         record in the Commission files.

3.       A manually  signed  copy of the form and  amendments  thereto  shall be
         filed  with each  national  securities  exchange  on which any class of
         securities of the registrant is registered.

4.       Amendments to the  notifications  must be filed on form 12b-25 but need
         not restate  information  that has been correctly  furnished.  The form
         shall be clearly identified as an amended notification.

5.       Electronic  Filers.  This form shall not be used by  electronic  filers
         unable to timely file a report solely due to  electronic  difficulties.
         Filers unable to submit a report within the time period  prescribed due
         to difficulties in electronic filing should comply with either Rule 201
         or  Rule  202 of  Regulation  S-T  (ss.232.201  or  ss.232.202  of this
         chapter) or apply for an  adjustment  in filing  date  pursuant to Rule
         13(b) of Regulation S-T (ss.232.13(b) of this chapter).




© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission